Back to Search
Start Over
Pure red-cell aplasia and epoetin therapy
- Source :
- The New England Journal of Medicine. Sept 30, 2004, Vol. 351 Issue 14, p1403, 6 p.
- Publication Year :
- 2004
-
Abstract
- Reports of epoetin-associated pure red-cell aplasia from the Food and Drug Administration (FDA) and from the manufacturers of Eprex, Epogen and Neorecormon were obtained and analyzed. The results indicate a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex.
Details
- Language :
- English
- ISSN :
- 00284793
- Volume :
- 351
- Issue :
- 14
- Database :
- Gale General OneFile
- Journal :
- The New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.123739454